#Address correspondence to Adriana Pabón. Universidad de Antioquia, UdeA Calle 70 No. 52-21, Medellín, Colombia Tel: +574 219 6490. Fax: +574 219 6487. e-mail: [email protected]
In vitro Susceptibility of Plasmodium Vivax to antimalarials in Colombia 1
2
Diana Fernández1, César Segura1, Margarita Arboleda2, Giovanny Garavito3, Silvia Blair1, 3
Adriana Pabón1,4# 4
5
6
1 Grupo Malaria, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia. 7
2 Instituto Colombiano de Medicina Tropical, Universidad CES, Apartadó, Colombia. 8
3 Departamento de Farmacia, Facultad de Ciencias, Universidad Nacional de Colombia. 9
4 Programa de Biología, Facultad de Ciencias Básicas, Universidad del Atlántico, Barranquilla 10
Colombia. 11
12
13
Running title: Susceptibility of Colombian Plasmodium vivax isolates 14
Abstract word count: 211 15
Text word count: 3170 16
17
AAC Accepts, published online ahead of print on 11 August 2014Antimicrob. Agents Chemother. doi:10.1128/AAC.03191-14Copyright © 2014, American Society for Microbiology. All Rights Reserved.
on June 20, 2018 by guesthttp://aac.asm
.org/D
ownloaded from
[Escriba texto]
ABSTRACT 18
The In vitro susceptibility of 30 isolates of Plasmodium vivax to a number of antimalarials 19
(chloroquine, mefloquine, amodiaquine, quinine and artesunate) was evaluated. The isolates 20
came from the malaria-endemic region of Urabá in Colombia, and were evaluated by the 21
schizont maturation test. The IC50 was found to be 0.6 nM (CI 95%: 0.3 – 1.0nM) for 22
artesunate, 8.5nM (CI 95%: 5.6 – 13.0nM) for amodiaquine, 23.3nM (CI 95%: 12.4 – 44.1nM) 23
for chloroquine, 55.6nM (CI 95%: 36.8 – 84.1nM) for mefloquine and 115.3nM (CI 95%: 57.7 24
– 230.5nM) for quinine. The isolates were classified according to whether the initial parasites 25
were mature or immature trophozoites (Tfz). It was found that the IC50 values for chloroquine 26
and artesunate were significantly different in the two aforementioned groups (p<0.001). The 27
IC50 of CQ and AS was higher in the isolates from mature Tfz (CQ: 39.3 nM vs 17 nM, AS: 1.4 28
nM vs 0.3 nM) and 10% of the isolates showed lower susceptibility to one of the antimalarial, 29
13.3% to two antimalarial and 3.3% over three antimalarial drugs. It should be highlighted that 30
despite the extensive use of chloroquine in Colombia, P. vivax continues to be susceptible to 31
antimalarials. This is the first report, to our knowledge, showing in vitro susceptibility of P. 32
vivax isolates to antimalarials in Colombia. 33
34
Key words: Plasmodium vivax, in vitro susceptibility, Chloroquine, amodiaquine, mefloquine, 35
quinine and artesunate antimalarials 36
37
on June 20, 2018 by guesthttp://aac.asm
.org/D
ownloaded from
[Escriba texto]
INTRODUCTION 38
Plasmodium vivax is responsible for more than 50% of malaria cases worldwide and is 39
prevalent in Southeast Asia, the Western Pacific, Central and South America. P. vivax malaria 40
is known for causing relapses (1) and in recent years complicated clinical conditions have 41
been reported for this type of malaria that are similar to those found for P. falciparum. Indeed, 42
the aforementioned two species coexist in many parts of the world (2). In Colombia 85% of 43
the territory is suitable for the transmission of Plasmodium spp., and according to an 44
epidemiological report from the National Health Institute of Colombia, 53,963 cases of malaria 45
were reported in 2012, of which 40,314 (74.7%) corresponded to P. vivax malaria (3). 46
47
The therapeutic failure of chloroquine to treat P. vivax malaria has been reported in different 48
regions around the world. The first case of therapeutic failure was reported in Papua New 49
Guinea in 1989 (4, 5), and since then cases have also been recorded in Asia, principally in 50
Indonesia, Malaysia, Myanmar, India, The Philippines, Vietnam, Korea and Thailand. Cases 51
have also been reported in Ethiopia in Africa (6-12) and in Guyana, Brazil, Venezuela, Peru 52
and Colombia in South America (13-17). In Colombia, whereas one study reports the 53
therapeutic failure of chloroquine in 11% (3/27) of the patients evaluated (17), there are other 54
studies that report a 100% efficacy of this antimalarial (14, 18). Therefore, the In vitro 55
susceptibility profile of P. vivax to antimalarials must be determined. 56
on June 20, 2018 by guesthttp://aac.asm
.org/D
ownloaded from
[Escriba texto]
This work investigated In vitro susceptibility of fresh isolates of P. vivax from the region of 57
Urabá (Antioquia, Colombia) to chloroquine, mefloquine, amodiaquine, quinine and 58
artesunate using the schizont maturation test. 59
60
MATERIALS AND METHODS 61
Pre-dosing of plates with antimalarials: Seven serial dilutions of the antimalarials 62
chloroquine (CQ) (Sigma R-6628), mefloquine (MQ) (Sigma R-2319), amodiaquine (AQ) 63
(Sigma R-2799), quinine (Qn) (Sigma R-0132) and artesunate (Sigma R-3731) were pre-64
dosed. Each antimalarial plate was pre-dosed in triplicate, in a range of: 1.646 nM –1.200nM; 65
12.5nM – 800nM; 2.34nM – 150nM; 3.7nM – 2.700nM and 0.05nM – 40nM for CQ, MQ, AQ, 66
Qn and AS respectively (4, 19-22). The pre-dosed plates were stored at 4°C until they were 67
used. The quality control of the pre-dosing stage was carried out with the NF54 strain of P. 68
falciparum (sensitive to all known antimalarials) (23) and parasitaemia was recorded through 69
the radioisotope method (24). 70
P. vivax isolates: Between September 2010 and November 2012, at the malaria diagnosis 71
stations in the endemic municipalities of Turbo and Apartadó (Urabá, Antioquia, Colombia), 72
patients were received with the following inclusion criteria: any age and gender, women who 73
were not pregnant, single P. vivax infections (according to thick smear test and confirmed by 74
the rapid diagnostic test SD Bio Line malaria Ag Pf/Pan Standard diaagnostiscs Inc®, Ref. 75
05FK66) and parasitaemia > 2000 parasites/µL of blood. Additionally, the following inclusion 76
on June 20, 2018 by guesthttp://aac.asm
.org/D
ownloaded from
[Escriba texto]
criteria were applied: diagnosis of uncomplicated malaria according to the WHO criteria 77
adapted for Colombia (25), patients who hadn’t taken antimalarials the month before the test, 78
and patients who didn’t have chloroquine in their urine (according to the Saker-Solomons 79
method). Patients who fulfilled the criteria and were willing to take part signed an informed 80
consent previously approved by the Ethics Committee of the Universidad de Antioquia 81
through act number 012 of the 18th June 2009. In the case of minors, the consent was signed 82
by a parent or guardian over the age of 18. 83
Collecting and processing samples: In order to evaluate the in vitro susceptibility of P. 84
vivax to antimalarials, 10 mL of venous blood was taken from each patient and put in a 85
vacutainer tube with heparin. The samples were processed within four hours after collected 86
from the patients. Additionally, 200 µL of blood was poured onto filter paper (Ref: Whatman 87
#3) to confirm the P. vivax monoinfection in the analysed samples using PCR (26). 88
In the thick smear test, 200 asexual parasites were counted in all of the different parasitic 89
stages: rings or immature trophozoites (Tfz imm), amoeboid trophozoites (Tfz ameob), mature 90
trophozoites (Tfz mat), pre-schizonts (pre-sch) and mature schizonts (Sch mat) (27). 91
According to the initial parasitic stages, the isolates can be divided into two groups. Group 1 92
consists of isolates with more than 133 immature Tfz (rings + amoeboid Tfz) out of 200 93
asexual parasites, and Group 2 consists of isolates that do not fulfil the previous criterion and 94
present > 133 mature Tfz out of 200 asexual parasites (21, 27). 95
on June 20, 2018 by guesthttp://aac.asm
.org/D
ownloaded from
[Escriba texto]
Assay of in vitro susceptibility of P. vivax to antimalarials using the schizont 96
maturation method: Before the assay, the leukocytes in a 10 mL sample of heparinized 97
blood were eliminated during two rounds of filtration using cellulose columns, in accordance 98
with the method described by Rusell, et al, 2003 (22). The brand of cellulose (Sigma Aldrich, 99
S6288) used was different to that employed in Rusell´s method, but it had similar 100
characteristics. 101
The parasitized erythrocytes, recovered during the second filtration, were centrifuged at 1,500 102
rpm for 5 minutes. The supernatant liquid was then removed and 800 µL of the parasitized 103
erythrocytes was used to prepare a suspension at a hematocrit of 2% in McCoy’s 5A medium 104
(Sigma Aldrich, M4892), supplemented with 25% AB+ of human serum. 200 µL of this 105
suspension was poured into each well of the pre-dosed plates, which were incubated at 37°C 106
in an atmosphere of 5% CO2, 5% O2 and 90% N2 until 40% of the initial parasitic stages of 107
each isolate matured into schizonts in the drug-free control wells. After incubation, the 108
supernatant was removed from each well and the thick smear test was performed (28). To 109
obtain readings from the tests, 200 asexual parasites differentiated by their parasitic stages 110
were counted as previously described. 111
Inhibition percentages and inhibitory concentration (IC50): The inhibition percentage of 112
schizont maturation in the treatment was calculated by relating the number of schizonts 113
present in the controls (greater than 40%) with the number of schizonts in the treatments. 114
Calculations were made of the mean or median, standard deviation and coefficient of 115
variation of the schizont inhibition percentages obtained in three replicas of the antimalarial 116
on June 20, 2018 by guesthttp://aac.asm
.org/D
ownloaded from
[Escriba texto]
concentrations evaluated. The IC50s were estimated using a dose-response regression model 117
from the drug-free controls by the GraphPad Prism version 5.0 program. The IC50s that were 118
within the concentration range evaluated for each antimalarial, and that had an r2 > 9.0, were 119
classified as valid. The IC50 of each antimalarial was correlated with the antimalarial group to 120
which it belonged (aminoquinolines and artemisinins) in order to find overlapping 121
susceptibility. 122
Statistical analysis: The statistical analysis was carried out using the GraphPad Prism 123
version 5.0 software. The Kruskal-Wallis test was applied to determine the non-parametric 124
comparisons, and the Fisher test was employed to calculate statistical significance. The non-125
parametric correlation analysis was carried out using the Spearman (rs) correlation model. 126
127
RESULTS 128
Of the 68 P. vivax monoinfection isolates (confirmed by PCR) that fulfilled the inclusion 129
criteria, 30 (44.1%) achieved a schizont maturation of >40%. The mean initial parasitaemia 130
was 9853.3 parasites/µL of blood (CI 95%: 7640.7–17494.0). The isolates took an average of 131
28.8 hours (CI 95%: 25.7–31.9 hours) to reach a schizont maturation and each isolate 132
reached an average maturation of 54% (CI95%: 46 - 100). Of the evaluated isolates, 15 133
(50%) were classified in Group 1, with more than 133 immature tfz out of 200 asexual 134
parasites and a mean initial parasitaemia of 12,605 parasites/µL of blood [CI 95%: 8,985 – 135
16,226]. The other 15 (50%) were classified in Group 2, with more than 133 mature tfz out of 136
on June 20, 2018 by guesthttp://aac.asm
.org/D
ownloaded from
[Escriba texto]
200 asexual parasites and a mean initial parasitaemia of 6,949 parasites/µL of blood [CI95%: 137
4,749 – 9,150]. The parasitaemia was significantly different in the two groups (p value <0.05). 138
In Group 1, 66.7% (10/15) of the isolates achieved schizont maturation after 30 hours, 20% 139
(3/15) reached this stage after 40 hours and 13.3% (2/15) achieved maturation after 48 hours 140
and in Group 2, 73.3% (11/15) achieved maturation after 30 hours and the rest reached this 141
stage after 20 hours. The majority of cultures in both groups had a maturation time of 30 142
hours. The maturation time was significantly higher in the isolates of Group 1 than those of 143
Group 2 (p value < 0.0001) (Table 1). 144
In vitro susceptibility of P. vivax to antimalarials 145
The number of valid tests and the IC50 found for each antimalarial can be seen in Table 2. 146
Due to the fact that only 30 isolates matured successfully, the IC50 medians were analysed 147
based on the predominance of the initial parasitic stages, as shown in Table 3. The maximum 148
and minimum values of IC50 were found for CQ (2.5nM – 1109.0nM), MQ (10.6nM – 522.3 149
nM), AQ (2.7nM – 105.2nM), Qn (4.0nM – 1398.0nM) and AS (0.1nM – 10.7nM) (Figure 1). 150
151
Correlation of the IC50s of the different antimalarials in P. vivax from Colombia 152
The overlapping susceptibility of the 30 isolates of P. vivax to all of the antimalarials evaluated 153
is shown in Table 4. The susceptibility of the antimalarials CQ, MQ, AQ and Qn of the 154
quinoline group were compared with AS (a derivative of artemisinin). A positive correlation 155
was found between the CQ and the MQ with AS (p value < 0.001) (Table 4). 156
on June 20, 2018 by guesthttp://aac.asm
.org/D
ownloaded from
[Escriba texto]
DISCUSSION 157
This study analysed the susceptibility of 30 Colombian isolates of P. vivax to different 158
antimalarials. Chloroquine is a drug of special interest as it corresponds to a first-line 159
treatment for P. vivax malaria in Colombia (25). Given the difficulty of maintaining P. vivax in 160
continuous cultures (29-31), an in vitro short-term growth method was used which consisted 161
of maintaining the parasites in culture for periods of time of less than 48 hours until they 162
reached their schizont maturation (32). This method has helped to determine the in vitro 163
susceptibility of P. vivax to antimalarials in different geographic regions of Africa and Asia (20-164
22, 33-35). 165
166
The IC50s observed in the isolates from the region of Urabá, which is a low malaria-endemic 167
area for South America but a high endemic area for Colombia, were low for all of the 168
antimalarials. However, there were isolates that presented IC50 values for CQ that were 47.6 169
times higher than the mean IC50 (23.3 nM). Four out of 30 (13.3%) of the isolates presented 170
IC50 values greater than 100 nM, which is similar to what has been found in Asian countries 171
like Thailand, Indonesia, Myanmar, Papua New Guinea and Brazil (36) (Table 5). 172
It is important to note that the schizont maturation method gives variables like the level of 173
maturity of the parasitic stages at the beginning of the assay. These variables influence the 174
maturation time of the schizonts and the reproducibility of the results. This is one of the 175
possible reasons that the IC50 values of CQ and AS were significantly different (p<0001) in the 176
on June 20, 2018 by guesthttp://aac.asm
.org/D
ownloaded from
[Escriba texto]
two groups established according to initial parasitic stages, as has been reported previously 177
in the literature. Despite the differences found, the mean IC50 values for all of the antimalarials 178
were observed within the range of susceptibility, suggesting that the Colombian isolates were 179
susceptible even when they were cultured from mature trophozoites (21, 37). 180
Whereas in the case of P. falciparum the mature trophozoite is considered to be the target 181
stage of CQ, for P. vivax this target is not recognised. It is believed that each species has 182
characteristics that can explain the difference in susceptibility of each parasitic stage to 183
chloroquine (21, 37). During studies that monitor the resistance of P. vivax to antimalarials, it 184
is important to take into account the target parasite form. In this study, the cultures that began 185
with a predominance of mature forms (Group 2) presented significantly higher IC50 values 186
than those that began with immature forms (Group 1). 187
When determining the susceptibility of P. vivax to antimalarials, the monitoring of schizont 188
maturation is fundamental in order to avoid taking premature readings which would cause a 189
smaller percentage schizonts to be recorded than expected. However, an excess in 190
maturation time would cause the schizonts to rupture and their numbers would be reduced 191
(21). 192
The positive correlation observed between the susceptibility of the isolates to the quinolines 193
CQ, MQ, AQ, Qn and AS (a derivative of artemisinins) suggests a common mode of action, 194
as proposed by other authors (21, 27). Artesunate is a first-line drug for the treatment of P. 195
falciparum malaria in Colombia (25). This study shows that in Colombia AS is also effective 196
on June 20, 2018 by guesthttp://aac.asm
.org/D
ownloaded from
[Escriba texto]
against P. vivax, as an IC50 of 0.6 nM (CI 95%: 0.3 – 1.0nM) is presented. Studies carried out 197
between 2004 and 2009 in different regions of Asia, like Thailand and Indonesia, report an 198
IC50 of < 10 nM for the effect of artesunate against P. vivax. Such results suggest that 199
derivatives of artemisinins have been effective against this type of parasite. However, in 200
Thailand in the year 2011, an IC50 of 32.6 nM was found for artesunate and in South América, 201
in Brazilian region in the year 2014, an IC50 of 21.0 nM was found for this antimalarial which 202
suggests a susceptibility loss of P. vivax to this antimalarial in two different geographic 203
regions (Table 5) (9, 19, 21, 22, 36, 38). In this study, when the isolates were classified 204
according to the initial parasitic stages, IC50s for AS of 0.3 nM in Group 1 and 1.4 nM in Group 205
2 were found (Table 3). Although these values are significantly different, they are below 10 206
nM, which indicates that this antimalarial is effective against P. vivax in Colombia. With 207
respect to MQ, in this study an IC50 of 55.6 nM (Table 2) was found, which differs from the 208
values reported from 2008 to 2011 in Thailand, Indonesia and China, and from the values 209
reported for Thailand and Korea in 2004 and 2009 respectively (19, 33). In the case of AQ, an 210
IC50 of 8.5 nM (Table 2) was recorded, which is similar to the values reported in different 211
regions of Asia (IC50 < 30 nM) between the years of 2004 and 2008 (Table 5). (19, 22, 39). 212
This suggests that AQ is effective against P. vivax in the various geographical regions studied 213
in Asia and South America. Finally, the Qn in this study had an IC50 of 115.3 nM, which was 214
almost three times below the values reported in the literature (393.4 nM) (Table 5). However, 215
it should be noted that there are very few reports of quinine being evaluated in vitro against P. 216
vivax. More monitoring of this antimalarial in different geographical regions would help to 217
establish its affectivity. 218
on June 20, 2018 by guesthttp://aac.asm
.org/D
ownloaded from
[Escriba texto]
Given the difficulty of maintaining an in vitro culture of P. vivax (29-31), resistance studies 219
have been complimented with genetic markers. One example of a genetic marker is the 220
pvmdr-1 gene that encodes for the protein associated to multiple drug resistance. The 221
presence of mutations is associated to the loss of in vitro susceptibility of P. vivax to the 222
antimalarials. Furthermore, the mutations in the pvdhfr and pvdhpr genes of P. Vivax that 223
encode for the dihydrofolate reductase and dihydropteroate synthase proteins respectively 224
have shown to be associated with a loss of susceptibility to sulfadoxine/pyrimethamine (40). 225
In the year 2008, Suwanarusk R et al. evaluated how in vitro susceptibility is associated with 226
the presence of mutations in the pvmdr-1 gene (39). They found a significantly high IC50 (78.6 227
nM) for mefloquine and an increase in the number of copies of the pvmdr-1 gene compared 228
with isolates which had a low IC50 (38 nM) and a single copy of the gene. The presence of the 229
Y976F mutation of the pvmdr-1 gene has been associated with a greater loss of susceptibility 230
to CQ (IC50: 154 nM) compared to the isolations without mutation (IC50: 34 nM), but with a 231
greater susceptibility to artesunate (IC50 mutant: 1.8 nM vs native: 9.5 nM) and mefloquine 232
(IC50 mutant: 14 nM vs wild: 121 nM). 233
234
In Central America polymorphisms have been found in the pvmdr-1 and pvdhfr genes that 235
may be related to the loss of susceptibility of P. vivax to antimalarials. However, there is no 236
evidence from in vitro susceptibility studies that support this association (41). In South 237
America, only isolated cases of the therapeutic failure to CQ for the treatment of P. vivax 238
on June 20, 2018 by guesthttp://aac.asm
.org/D
ownloaded from
[Escriba texto]
malaria have been documented and no data on CQ drug levels to ensure therapeutic levels 239
were informed. Also there are few reports of in vitro susceptibility of P. vivax to antimalarials. 240
However, ongoing clinical efficacy monitoring would be important in addition to integrated in 241
vitro susceptibility and molecular markers studies. For example, in Amazonian region of 242
Brazil, in the year 2013, Chehuan et al., reported that 12 out of 112 (10.7%) isolates with IC50 243
> 100 nM where considered resistant to CQ, while 3 out of 47 (6.4%) where considered 244
resistant to MQ. The same study, it was shown that Amazonian P. vivax strains with both CQ 245
and MQ resistance may be common; and a non-synonymous mutation at Pvdhps codon 382 246
(S→C) was associated to in vitro susceptibility to CQ, thus further studies should be done to 247
confirm this observation (42). On the other hand, in the year 2014, Aguiar et al, found similar 248
IC50´s to those reported to CQ and MQ in this region however, the IC50´s to AS observed in 249
this work for Colombia was twenty times lower to that reported in Brazil (36) (Table 5). 250
251
In conclusion, this study showed that the Colombian isolates of P. vivax continue to be 252
susceptible to all of the antimalarials evaluated, and it is important to note that this is the first 253
report that has investigated the effect of the IC50s of antimalarials against P. vivax in 254
Colombia. However, the presence of isolates with IC50 values above 100 nM for CQ, MQ and 255
Qn suggests the need of monitoring periodically the therapeutic response to antimalarials and 256
the evaluation of antimalarial drugs levels in blood and importantly will be associate the IC50s 257
in vitro of antimalarials in P. vivax and their tendency to increase with an eventual therapeutic 258
on June 20, 2018 by guesthttp://aac.asm
.org/D
ownloaded from
[Escriba texto]
failure. It is also important to search for specific mutations in genetic markers in accordance 259
with the results reported by authors in Asia (10, 20, 21, 37, 39, 43-45). 260
261
ACKNOWLEDGEMENTS 262
The authors wish to thank Colciencias (code 111549326137, RC 488-2009) and the 263
Universidad de Antioquia, Colombia (CODI-Sustainability strategy 2013-2014 UdeA). The 264
authors would like to thank to the Instituto Colombiano de Medicina Tropical (ICMT), 265
Apartadó, for providing the conditions necessary to carry out the field work, and the hospitals 266
Antonio Roldán Betancur of the Municipality of Apartadó and Francisco Valderrama of the 267
Municipality of Turbo for their support in acquiring the patients. Furthermore, the authors wish 268
to thank: Dr. Omar Triana for his advice on the methodology, Gonzalo Alvarez for his help 269
with the statistics, the microbiologist and bioanalyst Gabriel Vélez for his support with the 270
experimental activities carried out in the laboratory at Apartadó and with the inclusion of 271
patients, the microbiologists and bioanalysts Claudia Patiño and Alexandra Ríos for their help 272
with the inclusion of patients and their support with field activities in Turbo, the Bacteriologist 273
Luz Yaned Usuga for acquiring patients in Apartadó, and the investigative assistant Fernando 274
Méndez for his support with the field activities. 275
276
BIBLIOGRAPHY 277
278
on June 20, 2018 by guesthttp://aac.asm
.org/D
ownloaded from
[Escriba texto]
1. Who. 2011. World Malaria Report 2011. 279
2. Price RN, Douglas NM, Anstey NM. 2009. New developments in Plasmodium vivax 280
malaria: severe disease and the rise of chloroquine resistance. Current Opinion in 281
Infectious Diseases 22:430-435. 282
3. Insitituo Nacional de Salud RdC. 2012. Boletín epidemiológico semanal. 283
4. Rieckmann KH, Davis DR, Hutton DC. 1989. Plasmodium vivax resistance to 284
chloroquine?, p. 1183-1184, vol. 2. 285
5. Schuurkamp GJ, Spicer PE, Kereu RK, Bulungol PK, Rieckmann KH. 1992. 286
Chloroquine-resistant Plasmodium vivax in Papua New Guinea, p. 121-122, vol. 86. 287
6. Fryauff DJ, Baird JK, Candradikusuma D, Masbar S, Sutamihardja MA, Leksana 288
B, Tuti S, Marwoto H, Richie T, Romzan A. 1997. Survey of in vivo sensitivity to 289
chloroquine by Plasmodium falciparum and P. vivax in Lombok, Indonesia. The 290
American Journal of Tropical Medicine and Hygiene 56:241-244. 291
7. Fryauff DJ, Sumawinata I, Purnomo, Richie TL, Tjitra E, Bangs MJ, Kadir A, 292
Ingkokusumo G. 1999. In vivo responses to antimalarials by Plasmodium falciparum 293
and Plasmodium vivax from isolated Gag Island off northwest Irian Jaya, Indonesia. 294
The American Journal of Tropical Medicine and Hygiene 60:542-546. 295
8. Muhamad P, Ruengweerayut R, Chacharoenkul W, Rungsihirunrat K, Na-296
Bangchang K. 2011. Monitoring of clinical efficacy and in vitro sensitivity of 297
Plasmodium vivax to chloroquine in area along Thai Myanmar border during 2009-298
2010. Malaria journal 10:44-44. 299
9. Pukrittayakamee S, Chantra A, Simpson JA, Vanijanonta S, Clemens R, 300
Looareesuwan S, White NJ. 2000. Therapeutic responses to different antimalarial 301
drugs in vivax malaria. Antimicrobial Agents and Chemotherapy 44:1680-1685. 302
10. Tan-ariya P, Na-Bangchang K, Tin T, Limpaibul L, Brockelman CR, Karbwang J. 303
1995. Clinical response and susceptibility in vitro of Plasmodium vivax to the standard 304
regimen of chloroquine in Thailand. Transactions of the Royal Society of Tropical 305
Medicine and Hygiene 89:426-429. 306
on June 20, 2018 by guesthttp://aac.asm
.org/D
ownloaded from
[Escriba texto]
11. Teka H, Petros B, Yamuah L, Tesfaye G, Elhassan I, Muchohi S, Kokwaro G, 307
Aseffa A, Engers H. 2008. Chloroquine-resistant Plasmodium vivax malaria in Debre 308
Zeit, Ethiopia. Malaria journal 7:220-220. 309
12. Yoda T, Rakue Y, Mizota T, Looareesuwan S. 2005. The efficacy of anti-malaria 310
drugs against Plasmodium vivax on the Thailand-Myanmar border. Journal Of Tokyo 311
Medical University 63:140-143. 312
13. Alecrim M Das G, Alecrim W, Macêdo V. 1999. Plasmodium vivax resistance to 313
chloroquine (R2) and mefloquine (R3) in Brazilian Amazon region, p. 67-68, vol. 32. 314
14. Alvarez LG, Piñeros JG, Tobón A, Ríos AM, Maestre AE, Blair S, Carmona J. 315
2007. Eficacia de tres esquemas con Cloroquina – Primaquina para el tratamiento de 316
la malaria por Plasmodium vivax en Colombia. CES Medicina 21:51-60. 317
15. Osorio L PLGI. 2007. Evaluación de la eficacia de los medicamentos antimaláricos en 318
Tarapacá, Amazonas colombiano. Biomédica 27:133-140. 319
16. Ruebush TK, Zegarra J, Cairo J, Andersen EM, Green M, Pillai DR, Marquiño W, 320
Huilca M, Arévalo E, Garcia C, Solary L, Kain KC. 2003. Chloroquine-resistant 321
Plasmodium vivax malaria in Peru. The American Journal of Tropical Medicine and 322
Hygiene 69:548-552. 323
17. Soto J, Toledo J, Gutierrez P, Luzz M, Llinas N, Cedeño N, Dunne M, Berman J. 324
2001. Plasmodium vivax clinically resistant to chloroquine in Colombia. 325
18. Rios A, Alvarez G, Blair S. 2013. [Ten years of chloroquine efficacy for uncomplicated 326
Plasmodium vivax malaria treatment, Turbo, Antioquia, 2002 and 2011]. Biomedica 327
33:429-438. 328
19. Chotivanich K, Udomsangpetch R, Chierakul W, Newton PN, Ruangveerayuth R, 329
Pukrittayakamee S, Looareesuwan S, White NJ. 2004. In vitro efficacy of 330
antimalarial drugs against Plasmodium vivax on the western border of Thailand. The 331
American Journal of Tropical Medicine and Hygiene 70:395-397. 332
20. Druilhe P, Brasseur P, Blanc C, Makler M. 2007. Improved assessment of 333
Plasmodium vivax response to antimalarial drugs by a colorimetric double-site 334
on June 20, 2018 by guesthttp://aac.asm
.org/D
ownloaded from
[Escriba texto]
plasmodium lactate dehydrogenase antigen capture enzyme-linked immunosorbent 335
assay. Antimicrobial Agents and Chemotherapy 51:2112-2116. 336
21. Russell B, Chalfein F, Prasetyorini B, Kenangalem E, Piera K, Suwanarusk R, 337
Brockman A, Prayoga P, Sugiarto P, Cheng Q, Tjitra E, Anstey NM, Price RN. 338
2008. Determinants of in vitro drug susceptibility testing of Plasmodium vivax. 339
Antimicrobial Agents and Chemotherapy 52:1040-1045. 340
22. Russell BM, Udomsangpetch R, Rieckmann KH, Kotecka BM, Coleman RE, 341
Sattabongkot J. 2003. Simple In Vitro Assay for Determining the Sensitivity of 342
Plasmodium vivax Isolates from Fresh Human Blood to Antimalarials in Areas where P. 343
vivax Is Endemic. Antimicrobial Agents and Chemotherapy 47:170-173. 344
23. Ponnudurai T, Leeuwenberg AD, Meuwissen JH. 1981. Chloroquine sensitivity of 345
isolates of Plasmodium falciparum adapted to in vitro culture. Transactions of the 346
Royal Society of Tropical Medicine and Hygiene 33:50-54. 347
24. Desjardins RE, Canfield CJ, Haynes JD, Chulay JD. 1979. Quantitative assessment 348
of antimalarial activity in vitro by a semiautomated microdilution technique. 349
Antimicrobial Agents and Chemotherapy 16:710-718. 350
25. Ministerio de la Protección Social RdC. 2010. Guía para la atención clínica integral 351
del paciente con malaria. 352
26. Singh B, Bobogare A, Cox-Singh J, Snounou G, Abdullah MS, Rahman HA. 1999. 353
A genus- and species-specific nested polymerase chain reaction malaria detection 354
assay for epidemiologic studies. The American Journal of Tropical Medicine and 355
Hygiene 60:687-692. 356
27. Tasanor O, Noedl H, Na-Bangchang K, Congpuong K, Sirichaisinthop J, 357
Wernsdorfer WH. 2002. An in vitro system for assessing the sensitivity of Plasmodium 358
vivax to chloroquine. Acta Tropica 83:49-61. 359
28. Moody Ah FSL. 1985. Versatile Field's strain. Clinical pathology 38:342-343. 360
29. Golenda CF, Li J, Rosenberg R. 1997. Continuous in vitro propagation of the malaria 361
parasite Plasmodium vivax. Proceedings of the National Academy of Sciences of the 362
United States of America 94:6786-6791. 363
on June 20, 2018 by guesthttp://aac.asm
.org/D
ownloaded from
[Escriba texto]
30. Panichakul T, Sattabongkot J, Chotivanich K, Sirichaisinthop J, Cui L, 364
Udomsangpetch R. 2007. Production of erythropoietic cells in vitro for continuous 365
culture of Plasmodium vivax. International Journal for Parasitology 37:1551-1557. 366
31. Udomsangpetch R, Somsri S, Panichakul T, Chotivanich K, Sirichaisinthop J, 367
Yang Z, Cui L, Sattabongkot J. 2007. Short-term in vitro culture of field isolates of 368
Plasmodium vivax using umbilical cord blood. Parasitology International 56:65-69. 369
32. Rieckmann Kh Campbell Gh SLJ, et al. 1978. Drug sensitivity of Plasmodium 370
falciparum: an in vitro microtechnique. Lancet 1:22--23. 371
33. Chotivanich K, Sattabongkot J, Choi YK, Park JS, Sritabal J, Lim CS, 372
Udomsangpetch R, White NJ, Lee WJ. 2009. Antimalarial drug susceptibility of 373
Plasmodium vivax in the Republic of Korea. The American Journal of Tropical 374
Medicine and Hygiene 80:902-904. 375
34. Kosaisavee V, Suwanarusk R, Nosten F, Kyle DE, Barrends M, Jones J, Price R, 376
Russell B, Lek-Uthai U. 2006. Plasmodium vivax: isotopic, PicoGreen, and 377
microscopic assays for measuring chloroquine sensitivity in fresh and cryopreserved 378
isolates. Experimental Parasitology 114:34-39. 379
35. Renapurkar DM, Pradhan VR, Sutar NK, Deshmukh RA, Pandit CH, Marathe SN. 380
1989. Micro test for assaying sensitivity of Plasmodium vivax in vitro. Chemotherapy 381
35:160-163. 382
36. Aguiar AC, Pereira DB, Amaral NS, De Marco L, Krettli AU. 2014. Plasmodium 383
vivax and Plasmodium falciparum ex vivo susceptibility to anti-malarials and gene 384
characterization in Rondonia, West Amazon, Brazil. Malaria journal 13:73. 385
37. Sharrock WW, Suwanarusk R, Lek-Uthai U, Edstein MD, Kosaisavee V, Travers T, 386
Jaidee A, Sriprawat K, Price RN, Nosten F, Russell B. 2008. Plasmodium vivax 387
trophozoites insensitive to chloroquine. Malaria journal 7:94-94. 388
38. Lu F, Gao Q, Chotivanich K, Xia H, Cao J, Udomsangpetch R, Cui L, 389
Sattabongkot J. 2011. In vitro anti-malarial drug susceptibility of temperate 390
Plasmodium vivax from central China. The American Journal of Tropical Medicine and 391
Hygiene 85:197-201. 392
on June 20, 2018 by guesthttp://aac.asm
.org/D
ownloaded from
[Escriba texto]
39. Suwanarusk R, Chavchich M, Russell B, Jaidee A, Chalfein F, Barends M, 393
Prasetyorini B, Kenangalem E, Piera KA, Lek-Uthai U, Anstey NM, Tjitra E, 394
Nosten F, Cheng Q, Price RN. 2008. Amplification of pvmdr1 associated with 395
multidrug-resistant Plasmodium vivax. The Journal of Infectious Diseases 198:1558-396
1564. 397
40. Barnadas C, Tichit M, Bouchier C, Ratsimbasoa A, Randrianasolo L, Raherinjafy 398
R, Jahevitra M, Picot S, Ménard D. 2008. Plasmodium vivax dhfr and dhps mutations 399
in isolates from Madagascar and therapeutic response to sulphadoxine-pyrimethamine. 400
Malaria journal 7:35-35. 401
41. Jovel IT, Mejía RE, Banegas E, Piedade R, Alger J, Fontecha G, Ferreira PE, 402
Veiga MI, Enamorado IG, Bjorkman A, Ursing J. 2011. Drug resistance associated 403
genetic polymorphisms in Plasmodium falciparum and Plasmodium vivax collected in 404
Honduras, Central America. Malaria journal 10:376-376. 405
42. Chehuan YF, Costa MR, Costa JS, Alecrim MG, Nogueira F, Silveira H, Brasil LW, 406
Melo GC, Monteiro WM, Lacerda MV. 2013. In vitro chloroquine resistance for 407
Plasmodium vivax isolates from the Western Brazilian Amazon. Malaria journal 12:226. 408
43. Hamedi Y, Safa O, Zare S, Tan-ariya P, Kojima S, Looareesuwan S. 2004. 409
Therapeutic efficacy of artesunate in Plasmodium vivax malaria in Thailand. Southeast 410
Asian J Trop Med Public Health 35:570-574. 411
44. Suwanarusk R, Russell B, Chavchich M, Chalfein F, Kenangalem E, Kosaisavee 412
V, Prasetyorini B, Piera KA, Barends M, Brockman A, Lek-Uthai U, Anstey NM, 413
Tjitra E, Nosten F, Cheng Q, Price RN. 2007. Chloroquine Resistant Plasmodium 414
vivax: In Vitro Characterisation and Association with Molecular Polymorphisms. PLoS 415
ONE 2:9-9. 416
45. Treiber M, Wernsdorfer G, Wiedermann U, Congpuong K, Sirichaisinthop J, 417
Wernsdorfer WH. 2011. Sensitivity of Plasmodium vivax to chloroquine, mefloquine, 418
artemisinin and atovaquone in north-western Thailand. Wiener Klinische Wochenschrift 419
123 Suppl:20-25. 420
421
on June 20, 2018 by guesthttp://aac.asm
.org/D
ownloaded from
[Escriba texto]
FIGURES AND TABLES 422
Figure1. Geometric mean of the IC50 of antimalarials in P. Vivax isolates, Urabá, 423
Colombia. 424
425
426
427
on June 20, 2018 by guesthttp://aac.asm
.org/D
ownloaded from
[Escriba texto]
Table 1. Parasitic stages, maturation time and the percentage of schizonts obtained by the 428
isolate groups. 429
430
Characteristics of the
isolates pre and post
culture
Isolates Group 1 a
(n=15)
Isolates Group 2 b
(n=15) F - test
Mean (CI 95%) Mean CI 95%
Immature Tfz (a+Ta)* 172.2 (161.1 – 183.3) 18.33 (0.0 – 38.5) <0.0001
Mature Tfz* 23.3 (13.8 – 32.9) 174.7 (151.4 – 198.1) <0.0001
Pre- schizonts* 3.0 (0.7 – 5.3) 1.4 (0.2 – 2.6) 0.19
Schizonts* 1.5 (0.2 – 2.8) 5.5 (0.0 – 14.1) 0.32
Maturation time
(hours) 34.9 (31.0 – 38.8) 22.7 (20.1 – 25.2) <0.0001
% Schizonts post
maturation 59.9 (46.5 – 76.4) 48 (39.2 – 56.8) 0.12
* Count of differential stages at the beginning of the assay carried out with 200 asexual 431
parasites. aGroup 1: Isolates with predominance of immature trophozoites. bGroup 2: Isolates 432
with predominance of mature trophozoites. 433
434
on June 20, 2018 by guesthttp://aac.asm
.org/D
ownloaded from
[Escriba texto]
Table 2. IC50 of the antimalarials evaluated in the isolates of P. vivax, Urabá, Colombia 435
436
Antimalarial N° of valid assays* (%) IC50** (CI95%)
Chloroquine 30 (100) 23.3 (12.4 – 44.1)
mefloquine 28 (93.3) 55.6 (36.8 – 84.0)
Amodiaquine 26 (86.7) 8.5 (5.6 – 13.0)
Quinine 28 (93.3) 115.3 (57.7 – 230.5)
Artesunate 26 (86.7) 0.6 (0.3 – 1.0)
*Number of valid assays with IC50s over total number of assays (n=30). 437
**IC50: Geometric mean of the inhibitory concentration in nM. CI 95%: Confidence interval 438
95%.439
on June 20, 2018 by guesthttp://aac.asm
.org/D
ownloaded from
[Escriba texto]
Table 3. Comparison of the IC50 medians of each antimalarial based on initial parasitic stages 440
in the P. Vivax isolates. 441
442
Antimalarial
Group 1* Group 2* F – test
(n) Median of IC50**
(IQR) (n)
Median of IC50**
(IQR) P value
Chloroquine 15 17.0 (3.2 – 59.8) 15 39.3 (11.5 – 73.7) <0.0001
Mefloquine 13 24.1 (17.3 – 58.8) 15 72.2 (37.4 – 169.5) 0.644
Amodiaquine 12 3.7 (3.0 – 31.6) 14 7.2 (4.6 – 17.5) 0.199
Quinine 14 65.0 (24.8 – 946.2) 14 209.2 (53.5 – 378.3) 0.301
Artesunate 12 0.3 (0.1 – 1.0) 14 1.4 (0.2 – 2.0) <0.0001
IQR: Interquartile range 25% - 75%. 443
*Isolates with valid IC50 values for each antimalarial. F – test: Analysis of statistical 444
significance. 445
**Analysis of the median of the concentration that inhibits 50% of the maturation of the 446
schizonts, in nM. 447
448
on June 20, 2018 by guesthttp://aac.asm
.org/D
ownloaded from
[Escriba texto]
Table 4. Overlapping susceptibility of P. vivax among the different antimalarials. 449
450
COMBINATIONS Mefloquine Amodiaquine Quinine Artesunate
Chloroquine 0.557 ** 0.489 * 0.457 * 0.689 ***
Mefloquine -- 0.456 * 0.564 ** 0.639 ***
Amodiaquine -- -- 0.475 * 0.414 *
Quinine -- -- -- 0.483 *
Spearman correlation coefficient (rs). Correlations are shown of the in vitro susceptibility of the 451
Colombian isolates of P. vivax to all of the antimalarials evaluated. Statistical significance is 452
designated as: p<0.001 (***); p<0.01 (**); and p<0.05 (*). A positive correlation among the 453
antimalarials evaluated can be seen. 454
on June 20, 2018 by guesthttp://aac.asm
.org/D
ownloaded from
[Escriba texto]
Table 5. Susceptibility profile of the P. vivax isolates to antimalarials in different geographical regions. 455
456
Geometric mean of IC50 (nM) of antimalarials reported in the literature
Year Region Successful
assays CQ MQ AQ AS Qn Reference
1995 Thailand 57 360.5* -- -- -- -- (10)
2002 Thailand 121 50.3** -- -- -- -- (27)
2003 Thailand 34 96.5 -- -- -- -- (22)
2004 Thailand 20 96.9 335.9 30.1 1.3 393.4 (19)
2007 Thailand 81 46.8 -- -- -- --
(42) Indonesia 145 312* -- -- -- --
2007 Myanmar 2
15
>100*
<100 -- -- -- -- (20)
2008 Thailand ND 12+ -- -- -- --
(36) ND 415++ -- -- -- --
2008 Indonesia 216 295* 12.7 15.4 1.31 -- (21)
55.2+ 7.9+ 16.6+ -- --
on June 20, 2018 by guesthttp://aac.asm
.org/D
ownloaded from
[Escriba texto]
2812++ 12.5++ 24.2++ -- --
2008 Thailand 65 36.7 111 34 8.3 --
(38) Indonesia 85 114* 9.87 13.7 1.4 --
2009 Korea
Tailandia
50
24
75.6
96.9
103.2
335.9
--
--
1.5
1.3
75.4
393.4 (33)
2011 Thailand 34 167.2* 139.4 -- 32.6 -- (43)
2011 China 42 12.6 11.2 -- 0.3 -- (37)
2014 Brazil 32 32 57 -- 21 -- (36)
This
study Colombia 30 23.3 55.6 8.5 0.6 115.3
457
ND: No data; S: Susceptible; --: Not analyzed in the study. *: The authors suggest loss of susceptibility to 458
chloroquine when the IC50 is greater than 100 nM. +: Ring stage. ++: Trophozoite mature stage. 459
460
on June 20, 2018 by guesthttp://aac.asm
.org/D
ownloaded from
Figure1. Geometric mean of the IC50 of antimalarials in P. Vivax isolates, Urabá, Colombia.
on June 20, 2018 by guesthttp://aac.asm
.org/D
ownloaded from
#Address correspondence to Adriana Pabón. Universidad de Antioquia, UdeA Calle 70 No. 52-21, Medellín, Colombia Tel: +574 219 6490. Fax: +574 219 6487. e-mail: [email protected]
Table 1. Parasitic stages, maturation time and the percentage of schizonts obtained by the 1
isolate groups. 2
3
Characteristics of the
isolates pre and post
culture
Isolates Group 1 a
(n=15)
Isolates Group 2 b
(n=15) F - test
Mean (CI 95%) Mean CI 95%
Immature Tfz (a+Ta)* 172.2 (161.1 – 183.3) 18.33 (0.0 – 38.5) <0.0001
Mature Tfz* 23.3 (13.8 – 32.9) 174.7 (151.4 – 198.1) <0.0001
Pre- schizonts* 3.0 (0.7 – 5.3) 1.4 (0.2 – 2.6) 0.19
Schizonts* 1.5 (0.2 – 2.8) 5.5 (0.0 – 14.1) 0.32
Maturation time
(hours) 34.9 (31.0 – 38.8) 22.7 (20.1 – 25.2) <0.0001
% Schizonts post
maturation 59.9 (46.5 – 76.4) 48 (39.2 – 56.8) 0.12
* Count of differential stages at the beginning of the assay carried out with 200 asexual 4 parasites. aGroup 1: Isolates with predominance of immature trophozoites. bGroup 2: Isolates 5 with predominance of mature trophozoites. 6
7
on June 20, 2018 by guesthttp://aac.asm
.org/D
ownloaded from
[Escriba texto]
Table 2. IC50 of the antimalarials evaluated in the isolates of P. vivax, Urabá, Colombia 8
9
Antimalarial N° of valid assays* (%) IC50** (CI95%)
Chloroquine 30 (100) 23.3 (12.4 – 44.1)
mefloquine 28 (93.3) 55.6 (36.8 – 84.0)
Amodiaquine 26 (86.7) 8.5 (5.6 – 13.0)
Quinine 28 (93.3) 115.3 (57.7 – 230.5)
Artesunate 26 (86.7) 0.6 (0.3 – 1.0)
*Number of valid assays with IC50s over total number of assays (n=30). 10 **IC50: Geometric mean of the inhibitory concentration in nM. CI 95%: Confidence interval 11 95%.12
on June 20, 2018 by guesthttp://aac.asm
.org/D
ownloaded from
[Escriba texto]
Table 3. Comparison of the IC50 medians of each antimalarial based on initial parasitic stages 13 in the P. Vivax isolates. 14 15
Antimalarial
Group 1* Group 2* F – test
(n) Median of IC50**
(IQR) (n)
Median of IC50**
(IQR) P value
Chloroquine 15 17.0 (3.2 – 59.8) 15 39.3 (11.5 – 73.7) <0.0001
Mefloquine 13 24.1 (17.3 – 58.8) 15 72.2 (37.4 – 169.5) 0.644
Amodiaquine 12 3.7 (3.0 – 31.6) 14 7.2 (4.6 – 17.5) 0.199
Quinine 14 65.0 (24.8 – 946.2) 14 209.2 (53.5 – 378.3) 0.301
Artesunate 12 0.3 (0.1 – 1.0) 14 1.4 (0.2 – 2.0) <0.0001
IQR: Interquartile range 25% - 75%. 16 *Isolates with valid IC50 values for each antimalarial. F – test: Analysis of statistical 17 significance. 18 **Analysis of the median of the concentration that inhibits 50% of the maturation of the 19 schizonts, in nM. 20
21
on June 20, 2018 by guesthttp://aac.asm
.org/D
ownloaded from
[Escriba texto]
Table 4. Overlapping susceptibility of P. vivax among the different antimalarials. 22
23
COMBINATIONS Mefloquine Amodiaquine Quinine Artesunate
Chloroquine 0.557 ** 0.489 * 0.457 * 0.689 ***
Mefloquine -- 0.456 * 0.564 ** 0.639 ***
Amodiaquine -- -- 0.475 * 0.414 *
Quinine -- -- -- 0.483 *
Spearman correlation coefficient (rs). Correlations are shown of the in vitro susceptibility of the 24 Colombian isolates of P. vivax to all of the antimalarials evaluated. Statistical significance is 25 designated as: p<0.001 (***); p<0.01 (**); and p<0.05 (*). A positive correlation among the 26 antimalarials evaluated can be seen. 27
on June 20, 2018 by guesthttp://aac.asm
.org/D
ownloaded from
[Escriba texto]
Table 5. Susceptibility profile of the P. vivax isolates to antimalarials in different geographical regions. 28
29
Geometric mean of IC50 (nM) of antimalarials reported in the literature
Year Region Successful
assays CQ MQ AQ AS Qn Reference
1995 Thailand 57 360.5* -- -- -- -- (10)
2002 Thailand 121 50.3** -- -- -- -- (27)
2003 Thailand 34 96.5 -- -- -- -- (22)
2004 Thailand 20 96.9 335.9 30.1 1.3 393.4 (19)
2007 Thailand 81 46.8 -- -- -- --
(42) Indonesia 145 312* -- -- -- --
2007 Myanmar 2
15
>100*
<100 -- -- -- -- (20)
2008 Thailand ND 12+ -- -- -- --
(36) ND 415++ -- -- -- --
2008 Indonesia 216 295* 12.7 15.4 1.31 -- (21)
55.2+ 7.9+ 16.6+ -- --
on June 20, 2018 by guesthttp://aac.asm
.org/D
ownloaded from
[Escriba texto]
2812++ 12.5++ 24.2++ -- --
2008 Thailand 65 36.7 111 34 8.3 --
(38) Indonesia 85 114* 9.87 13.7 1.4 --
2009 Korea
Tailandia
50
24
75.6
96.9
103.2
335.9
--
--
1.5
1.3
75.4
393.4 (33)
2011 Thailand 34 167.2* 139.4 -- 32.6 -- (43)
2011 China 42 12.6 11.2 -- 0.3 -- (37)
2014 Brazil 32 32 57 -- 21 -- (36)
This
study Colombia 30 23.3 55.6 8.5 0.6 115.3
30 ND: No data; S: Susceptible; --: Not analyzed in the study. *: The authors suggest loss of susceptibility to 31 chloroquine when the IC50 is greater than 100 nM. +: Ring stage. ++: Trophozoite mature stage. 32 33
on June 20, 2018 by guesthttp://aac.asm
.org/D
ownloaded from